Insmed (INSM) Jefferies London Healthcare Conference 2025 summary

Recent achievements and pipeline progress

• Successful ASPEN trial readout and FDA approval of brensocatib for bronchiectasis, with early launch showing $28 million in partial quarter revenue and broad prescribing patterns.

• TPIP demonstrated strong efficacy in PAH, with plans for four phase 3 trials in PAH, PH-ILD, IPF, and PPF, aiming for best-in-class status and substantial market opportunities.

• ARIKAYCE, already approved for refractory MAC lung disease, anticipates ENCORE trial readout to expand its addressable market from 30,000 to 250,000 patients.

• Brensocatib is being studied for CRS and HS, with CRS data expected by early January and HS in the first half of next year; CRS could represent a larger market than bronchiectasis.

• Next-generation DPP-1 inhibitors are entering the clinic next year for major indications like rheumatoid arthritis, IBD, COPD, and asthma.

Commercial strategy and market expansion

• Focus on multi-franchise commercial execution, leveraging existing salesforce for both ARIKAYCE and brensocatib launches in the U.S., Europe, and Japan.

• List price parity approach for U.S., Europe, and Japan, with sensitivity to MFN pressures and willingness to forgo markets with unsustainable pricing.

• Market access decisions for brensocatib are expected to be finalized between now and Q1 next year, with efforts to ensure frictionless uptake and reauthorization.

• COPD and asthma patients represent significant future expansion opportunities, with millions potentially eligible based on comorbidities.

• Revenue from brensocatib is expected to outpace R&D expenses, supporting a path to cash flow positivity.

Research and development priorities

• Nearly 30 preclinical programs span gene therapy, deimmunized proteins, and synthetic rescue for CNS disorders, with several gene therapy programs entering the clinic next year.

• AI-driven deimmunized ARIKAYCE program expected to enter the clinic in 2027, aiming for a landmark achievement.

• Selective business development will target novel mechanisms of action with high return potential and low upfront costs.

• Gene therapy programs for DMD, ALS, and Stargardt are progressing, with ALS representing a potential blockbuster if successful.

• The company is positioned for significant value creation if CRS readout is positive, potentially unlocking broad applicability for DPP-1 inhibitors across multiple diseases.